Want to see SE:LARK full AI Analyst Report?
Top Page
CombiGene AB
(LARK)
Select Model
Select Model
Rating:50Neutral
Price Target:
kr2.00
▼(-9.09% Downside)
Action:Reiterated
Date:09/06/26
Overall score is held back primarily by weak financial performance quality: negative operating profitability and continued cash burn outweigh the benefit of a debt-free, well-capitalized balance sheet. Technicals are neutral-to-slightly weak with the stock below key moving averages. Valuation is mixed, with a high P/E limiting attractiveness despite an unusually high dividend yield.
Positive Factors
Debt-Free Balance Sheet
A debt-free structure and substantial equity base reduce financial risk and provide resilience while the company advances its programs. This capital position can preserve strategic flexibility and limit financing pressure during continued research and development investment.
Negative Factors
Persistent Cash Burn
Persistent negative operating and free cash flow means the business is not yet self-funding its activities. Continued cash consumption can require additional capital or transactions to sustain development, reducing flexibility even though the balance sheet currently carries no debt.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
A debt-free structure and substantial equity base reduce financial risk and provide resilience while the company advances its programs. This capital position can preserve strategic flexibility and limit financing pressure during continued research and development investment.
Read all positive factors
CombiGene AB (LARK) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr43.76M
Dividend Yield90.5%
Average Volume (3M)10.98K
Price to Earnings (P/E)36.5
Beta (1Y)0.04
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees5
SectorFinancial
Sector Strength70
IndustryAsset Management
Share Statistics
EPS (TTM)0.06
Shares Outstanding19,801,197
10 Day Avg. Volume10,164
30 Day Avg. Volume10,980
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.81
Price to Sales (P/S)0.00
P/FCF Ratio-3.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CombiGene AB Business Overview & Revenue Model
Company Description
Lärkberget AB (publ) functions as an investment firm, engaging in a variety of financial endeavors. Its operations encompass direct capital deployment into low-risk instruments, broader financial investments, acquiring stakes in privately held yet...
CombiGene AB Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
74
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 642.00K | 0.00 | 326.00K | 5.54M | 26.70M | 84.04M |
| Gross Profit | -2.14M | -8.16M | -46.78M | -21.29M | -19.20M | 15.16M |
| EBITDA | 2.72M | -7.19M | -34.22M | -35.98M | -5.86M | 23.56M |
| Net Income | 1.20M | -12.36M | -44.88M | -35.66M | -6.16M | 20.96M |
Balance Sheet | ||||||
| Total Assets | 57.56M | 56.73M | 75.88M | 120.61M | 158.22M | 166.22M |
| Cash, Cash Equivalents and Short-Term Investments | 6.17M | 5.84M | 73.75M | 101.44M | 131.78M | 136.74M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 846.00K | 1.24M | 4.30M | 4.16M | 6.10M | 7.94M |
| Stockholders Equity | 56.71M | 55.49M | 71.58M | 116.46M | 152.12M | 158.28M |
Cash Flow | ||||||
| Free Cash Flow | -2.57M | -12.78M | -29.95M | -30.67M | -16.67M | 21.97M |
| Operating Cash Flow | -2.57M | -12.78M | -29.95M | -30.56M | -16.67M | 22.11M |
| Investing Cash Flow | -49.97M | -49.78M | -81.00K | -988.90K | 0.00 | -147.73K |
| Financing Cash Flow | 0.00 | -3.96M | 0.00 | 0.00 | 0.00 | 65.88M |
CombiGene AB Technical Analysis
Negative
2.20
Price Trends
2.24
Negative
2.24
Negative
2.25
Negative
Market Momentum
<0.01
Negative
47.59
Neutral
51.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:LARK, the sentiment is Negative. The current price of 2.2 is below the 20-day moving average (MA) of 2.23, below the 50-day MA of 2.24, and below the 200-day MA of 2.25, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 47.59 is Neutral, neither overbought nor oversold. The STOCH value of 51.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:LARK.
CombiGene AB Peers Comparison
UnderperformOutperform
Sector (68)
SE:LARK
CombiGene AB
2.21
-0.28
-11.24%
SE:ATIN
Athanase Innovation AB
20.40
2.40
13.33%
SE:EQT
EQT AB
319.30
-7.14
-2.19%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.